Inflammatory Bowel Disease: A Personalized Approach. by Konidari, Anastasia et al.
OPINION
published: 11 February 2021
doi: 10.3389/fped.2020.620545
Frontiers in Pediatrics | www.frontiersin.org 1 February 2021 | Volume 8 | Article 620545
Edited by:
Andrew S. Day,
University of Otago, New Zealand
Reviewed by:
Madhur Ravikumara,





This article was submitted to
Pediatric Gastroenterology,
Hepatology and Nutrition,
a section of the journal
Frontiers in Pediatrics
Received: 23 October 2020
Accepted: 30 December 2020
Published: 11 February 2021
Citation:
Konidari A, Dickens D and
Pirmohamed M (2021) Inflammatory
Bowel Disease: A Personalized
Approach. Front. Pediatr. 8:620545.
doi: 10.3389/fped.2020.620545
Inflammatory Bowel Disease: A
Personalized Approach
Anastasia Konidari 1,2*, David Dickens 2 and Munir Pirmohamed 2
1 B Pediatric Clinic, Paidon Aglaia Kyriakou Children’s Hospital, Athens, Greece, 2 The Wolfson Centre for Personalized
Medicine, Institute of Systems, Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom
Keywords: inflammatory bowel disease, personalized medicine, therapeutics, genetic susceptibility, childhood
INTRODUCTION
Inflammatory bowel disease (IBD) encompasses three major forms of chronic intestinal
inflammation, including Crohn’s disease (CD), ulcerative colitis (UC), and unclassified IBD
(IBDU), previously known as indeterminate colitis. The definition of clinical phenotypes follows
internationally agreed standards based on a constellation of clinical, endoscopic, radiologic, and
histologic features. IBD is recognized as a heterogeneous spectrum of disorders with distinct clinical
courses and symptom chronicity, which may present anytime from early childhood to adulthood
(1–3). The burden of disease can be modified by treatment, but in principle, IBD presents with
relapsing and remitting course throughout life (4). CD and UC, while sharing several similar
pathologic and clinical features, have distinct differences in prognosis andmanagement (5). Disease
type and distribution in part influence disease progression and prognosis (6, 7).
Pediatric IBD is associated with greater disease burden and morbidity because it affects children
at a critical period for growth and development. It is characterized by extensive and severe
disease, which, if untreated, results in increased risk of intestinal strictures necessitating surgical
treatment (8), growth failure, nutritional deficiencies, delayed puberty, metabolic bone disease,
and increased risk of extra-intestinal manifestations such as hepatic, eye and skin disease, and
psychiatric morbidity (9–11).
GENETIC SUSCEPTIBILITY
IBD is a heterogeneous disorder with multifactorial etiology (12); mapping of the interaction
between genetic and environmental factors may inform molecular classification of disease in the
future (13, 14). Over the last decade, various studies have reported that multiple genomic loci
increase genetic susceptibility to IBD (15). Genome-wide association (GWA) and other studies
have demonstrated how genetics can be applied for phenotype stratification (16, 17); such studies
have provided an overview of relative contribution of various genomic loci to a number of human
diseases including IBD, through genotyping of a large number of single-nucleotide polymorphisms
(SNPs) across the human genome (18).
More than 163 IBD susceptibility genetic loci have been found in cohorts of European descent
(19), with emerging data of how genetic variation can determine disease distribution (20). Of these
loci, 110 confer risk to both IBD subtypes, whereas 30 and 23 loci are unique to CD and UC,
respectively. The 163 loci explain 13.6% of CD and 7.5% of UC total disease variance, respectively
(19). Liu et al. (21) have conducted the first trans-ethnic association study in IBD with use of GWA.
Immunochip data from 86,640 Europeans and 9,846 subjects of Asian descent revealed additional
38 IBD susceptibility loci; the majority show similar direction and magnitude of effect between
European and non-European populations (21).
Susceptibility genes encode proteins such as the nucleotide-binding oligomerization domain
protein 2 (NOD2) with mutations affecting nuclear factor-kappa beta (NFKB) production,
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autophagy-related 16-like protein 1 (ATG16L1), immunity-
related GTPase family M (IRGM), functional toll-like receptors
(TLRs) (22), signal transducer and activation of transcription
3 (STAT3) protein, and interleukin 23 receptor (IL-23R) (23).
Epigenetic alterations, such as DNA methylation, may further
influence disease progression (24).
CHILDHOOD-ONSET INFLAMMATORY
BOWEL DISEASE
IBD incidence and prevalence in children are increasing (25).
National cohort studies have been included in a recent systematic
review, which has confirmed the rising global trend of pediatric
IBD in both developed and developing countries (26). Emerging
evidence supports the need for a “top-down” approach in the
implementation of treatment modalities, especially in children
(27, 28). Furthermore, population-based cohort studies showed
twice the risk of developing corticosteroid (CS) dependency
within the first year from diagnosis in children, when compared
with adults (29). Early poor response to treatment and severe
disease extent at diagnosis as predictors of colectomy in pediatric
UC further support the need for early initiation of patient-
tailored treatment.
Until fairly recently, there has been a paucity of studies
about genes predisposing to childhood-onset IBD. A pediatric
GWA study by Cutler et al. (30) in 1,008 pediatric-onset IBD
patients and 1,633 controls confirmed overlap with common
adult IBD susceptibility loci such as NOD2 and IL23R. Denson
et al. (31) reported the results of whole-exome sequencing (WES)
in 543 children with IBD. Low/normal neutrophil intrinsic
granulocyte macrophage colony-stimulating factor (GM-CSF)
signaling was found to be associated with colony-stimulating
factor 2 receptor A subunit (CSF2RA)missense mutations, where
neutrophils from IBD patients exhibited alterations in gene
expression regulating cytokine production, wound healing, cell
survival, and proliferation (31). The same group performedWES
in children with IBD and healthy controls to identify mutations
in genes encoding nicotinamide adenine dinucleotide phosphate
oxidase (NADPH), and neutrophil gene expression associated
with reactive oxygen species production. Patients with specific
mutations in NADPH oxidases had more aggressive disease
course in CD (31).
Very-early-onset IBD (VEO-IBD) presents below 6 years
of age and manifests with a distinct phenotype, however, it
is not predominantly a monogenic condition; next-generation
sequencing such as WES or whole-genome screening (WGS)
may help establish the molecular diagnosis to some extent,
with a reported diagnostic yield varying between 13 and
26.5% (32), allowing for patient-specific early intervention the
opportunity to screen family members for carrier detection
and genetic counseling. IBD-like monogenic disorders are
related to primary immunodeficiency, for example, defects of T
and B lymphocyte selection and activation, disorders affecting
regulatory T cell activity, and interleukin 10 (IL10) and IL10
receptor A/B (IL10R) A/B signaling (33). Other monogenic
conditions include dysfunction of NADPH oxidase complex,
X-linked inhibitor of apoptosis (XIAP), lipopolysaccharide
responsive beige-like anchor protein (LRBA), cytotoxic T
lymphocyte-associated protein 4 (CTLA-4), STAT3, and chronic
granulomatous disease (34). Mutations in the epithelial cell
adhesion molecule (EPCAM), myosin Vb (MYO5B), Fork head
Box P3 gene (FOXBP3), Tetratricopeptide Repeat Domain
37 (TTC37) (35), and the “immune dysregulation, poly-
endocrinopathy, enteropathy, X-linked” syndrome (36) have
also been implicated in VEO-IBD. Tumor necrosis factor
alpha-induced protein 3 (TNFAIP3) mutations cause infantile-
onset IBD (37). Monogenic IBD is also caused by genes
related to intestinal epithelial defects, such as intestinal
epithelial cell adhesion and generation of reactive oxygen
species (38).
MODERN TREATMENT PARADIGMS
Therapeutic approaches involve potent inhibition of
inflammatory pathways and immune suppression. Complicated
disease course is largely associated with choice of treatment
agents, drug efficacy, and sustained treatment response or lack of
it. Medications are therefore not universally effective and can be
associated with significant toxicity (39).
Individual carriers of risk allele HLA DRB1 03:01 for
instance have been shown to be at 3-fold risk of 5ASA-related
nephrotoxicity (40).
Next-generation sequencing performed in leucocytes of
children with IBD at diagnosis and 4 weeks following
introduction of CS showed significantly altered expression
of 18 micro-RNAs; three of these micro-RNAs contained
glucocorticoid-responsive elements in their gene promoters and
could be putatively directly regulated by the GC receptor, while
others recognized 3
′
untranslated region of the GR gene (41).
Thiopurine drug monitoring is a successful paradigm
of personalized treatment. Thiopurine methyltransferase
(TPMT) genotyping is undertaken routinely prior to thiopurine
introduction in patients with IBD (42). Patient response to
treatment exhibits inter-individual variability thought to result
from variation in drug metabolism (43, 44). TPMT genotype and
activity can partially explain the variability in patient response.
Hematological toxicity, commonly manifesting as leukopenia,
is associated with the homozygous recessive TPMT genotype
and intermediate/low TPMT activity. Optimal 6TGN level is
a surrogate marker of response to thiopurine treatment; low
metabolite concentration is indicative of poor compliance (45).
6MMPR monitoring can be useful for early identification of liver
toxicity (43).
NUDT15 exon mutations have been associated with
thiopurine-induced leucopenia in Asian patients (46). Sutiman
et al. (47) have reported higher risk of thiopurine-induced
myelotoxicity in Asian patients with IBD. The Clinical
Pharmacogenetics Implementation Consortium has published
guidance on thiopurine dosing recommendations based on
TPMT and NUDT15 genotypes (48). Thiopurine-induced
pancreatitis has been related to HLA DQA1–HLA DRB1
homozygous haplotypes; however, this association has not
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been yet included in routine pre-treatment pharmacogenetic
panels (49).
There is emerging evidence about benefits of early anti-
TNF alpha administration (“top-down approach”) for
early disease remission, avoidance of later progression to
stricturing/penetrating disease in CD, improved quality of life,
and reduction of hospital admission rates (50, 51). Primary
loss of response to anti-TNF alpha occurs in up to a third of
patients, with up to half of the patients losing response over
time (52). There is preliminary evidence of HLA DQA1∗05
haplotype association with 2-fold increase of anti-TNF alpha
immunogenicity risk (53). The association of drug levels and
antibodies in relation to clinical outcomes requires further
investigation; however, recent systematic review and meta-
analysis overall support the finding that regular therapeutic drug
monitoring contributes to avoidance of higher disease relapse
rate (54).
Consideration of variable efflux transporter expression
associated with common genetic polymorphisms may also
influence response to treatment (55). Clinical response to CS
treatment for instance could be influenced by ABCB1 inter-
individual expression variability on the basis that CSs are ABCB1
substrates (56).
DISCUSSION
IBD patients cannot be treated with “one size fits all” approach,
because poor treatment response, adverse drug reactions, and
therapeutic failure result in increasing morbidity and health-
care costs (57). Loss of response or severe refractory disease
remains the main challenges that clinicians and patients face
during the disease course. Safety profile concerns such as
organ toxicity, accumulated cancer risk, and drug interactions
also influence clinician and patient choices. Best clinical
outcome with fewer drug-related adverse reactions result in
improved patient outcomes and optimal resource utilization;
these goals are at the heart of personalized medicine. Research
in patient-centered therapies based on the understanding of
disease pathogenesis, genetic susceptibility, and inter-individual
variability to treatment is ongoing (58, 59). The importance of
personalized treatment in children is indicated by recent studies
in childhood-onset CD, which have shown that non-sustained
response to treatment may be more important in predicting
disease relapse and overall complications than actual disease
severity and extent at diagnosis (60).
Research that involves large international consortia of
rigorously characterized patients is therefore paramount
in order to identify and validate clinically meaningful
and applicable biomarkers. This research requires large
patient numbers of different ethnicities for identification
of common and rare allele variants, with emphasis on
genotype/phenotype characterization and monitoring of
disease progression and treatment response. Cost issues pose
further challenges in this endeavor. The next frontier in
IBD therapeutics is about implementation of translational
pharmacogenetic associations in treatment algorithms,
in order to tailor pharmacotherapy to individual patient
profiles (61).
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